ZMYND8 and prostate cancer: ZMYND8 and KDM5D act as general negative regulators of enhancers in prostate cancer cells, and they antagonize the expression of these genes by recognizing the gene-activation-related dual-histone marker H3K4me1-H3K14ac [8].